Results of a study investigating polatuzumab vedotin combined with bendamustine and rituximab for relapsed diffuse large b-cell lymphoma.
Home / Resource Library / Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas